Edwards Martin — SEC Form 4 filings
SEC reporting owner CIK 1640073. 7 Form 4 filings on record with FilingPulse; latest filed 2025-10-08.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-04-30 to 2025-10-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 10,808 shares, $142,057 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 10,808 shares @ $13.14 ($142,057) in Verona Pharma plc, filed 2025-08-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Verona Pharma plc (VRNA) | Director | 4 | — | 1 leg · 10,808 sh · $142,057 | 12 |
| Morphic Holding, Inc. (MORF) | Director | 2 | — | — | 7 |
| Inozyme Pharma, Inc. (INZY) | Director | 1 | — | — | 1 |
Form 4 filings — Edwards Martin
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-08 | 4 | Verona Pharma plc (VRNA) | Disposition to issuer (D): 157,992 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | Verona Pharma plc (VRNA) | Option exercise (M): 24,000 @ $0 · Sale (S): 10,808 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | Morphic Holding, Inc. (MORF) | Disposition to issuer (D): 2,376 · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 9,996 (derivative) · Disposition to issuer (D): 17,550 (derivative) · Disposition to issuer (D): 12,535 (derivative) · Disposition to issuer (D): 23,168 (derivative) | EDGAR |
| 2024-06-20 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 23,168 (derivative) @ $0 | EDGAR |
| 2024-04-30 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1640073 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →